Summit Therapeutics (SMMT) Current Leases (2018 - 2026)

Summit Therapeutics (SMMT) has reported Current Leases for 9 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• Quarterly Current Leases rose 13.86% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 13.86% YoY) and the FY2025 annual result came in at $3.4 million, down 10.01% from the prior year.
• Current Leases improved to $3.6 million in Q2 2026 per SMMT's latest filing, from $3.2 million in the prior quarter.
• Over the last five years, Current Leases for SMMT reached as high as $3.8 million in Q3 2024 and fell as low as $684000.0 in Q2 2022.
• A 5-year average of $2.7 million and a median of $3.0 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases plunged 32.01% — and 2023, when it soared 328.07%.
• Year by year, Current Leases stood at $1.7 million in 2022, then jumped by 66.21% to $2.8 million in 2023, then soared by 34.03% to $3.8 million in 2024, then decreased by 10.01% to $3.4 million in 2025, then climbed by 4.78% to $3.6 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $3.6 million, $3.2 million, and $3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.